This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

This study has been completed.
Astellas Pharma US, Inc.
Information provided by:
Astellas Pharma Inc Identifier:
First received: November 22, 2005
Last updated: June 6, 2012
Last verified: June 2012
A study for the treatment of hormone refractory prostate cancer (HRPC) in patients previously treated with chemotherapy.

Condition Intervention Phase
Prostate Cancer Cancer of Prostate Prostatic Cancer Cancer of the Prostate Drug: YM155 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Astellas Pharma Inc:

Study Completion Date: March 2007

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed prostate cancer.
  • Prior chemotherapy regimen for prostate cancer

Exclusion Criteria:

  • History of other malignancy in the last 5 years
  • Major surgery within the past 21 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00257478

United States, Arizona
Tuscon, Arizona, United States, 85724
United States, California
Los Angeles, California, United States, 90033
United States, Idaho
Coeur d'Alene, Idaho, United States, 83814
United States, New York
Bronx, New York, United States, 10461
New York, New York, United States, 10016
United States, Pennsylvania
Philadelphia, Pennsylvania, United States, 19111
United States, Texas
San Antonio, Texas, United States, 78229
Amsterdam, Netherlands
United Kingdom
Sutton, Surry, United Kingdom, SM2 5Pt
Sponsors and Collaborators
Astellas Pharma Inc
Astellas Pharma US, Inc.
Study Director: D. Buell, MD Astellas Pharma US, Inc.
  More Information Identifier: NCT00257478     History of Changes
Other Study ID Numbers: 155-CL-007
Study First Received: November 22, 2005
Last Updated: June 6, 2012

Keywords provided by Astellas Pharma Inc:
Treatment Efficacy
Treatment Effectiveness
Disease Management

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases processed this record on August 22, 2017